ACM
PHAT icon

Altium Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Altium Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-220,000
Closed -$2.28M – 83
2023
Q3 		$2.28M Buy
220,000
+12,568
+6% +$172K 1.19% 28
2023
Q2 		$2.97M Buy
+207,432
New +$2.39M 2.25% 18

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Altium Capital Management's PHAT Position: Q4 2023 in Review

Altium Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q4 2023, closing a stake of 220,000 shares — an estimated $2.28M sold.

Altium Capital Management first reported a position in PHAT in Q2 2023 and held it in 2 quarters. The position peaked at $2.97M in Q2 2023. 117 funds tracked by Wall St. Rank hold PHAT as of Q4 2023.

  • Altium Capital Management reported no remaining Phathom Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Altium Capital Management sold 220,000 Phathom Pharmaceuticals shares in Q4 2023, an estimated $2.28M.
  • Altium Capital Management first reported a position in Phathom Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Altium Capital Management's Phathom Pharmaceuticals position peaked at $2.97M in Q2 2023.
  • 117 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2023.

Based on Altium Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.